An overview of HCV molecular biology, replication and immune responses

Hepatitis C virus (HCV) causes acute and chronic hepatitis which can eventually lead to permanent liver damage, hepatocellular carcinoma and death. Currently, there is no vaccine available for prevention of HCV infection due to high degree of strain variation. The current treatment of care, Pegylated interferon α in combination with ribavirin is costly, has significant side effects and fails to cure about half of all infections. In this review, we summarize molecular virology, replication and immune responses against HCV and discussed how HCV escape from adaptive and humoral immune responses. This advance knowledge will be helpful for development of vaccine against HCV and discovery of new medicines both from synthetic chemistry and natural sources.

• Publication year

  2011

• Venue

  Virology Journal

• Publication date

  2011-04-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1743-422X-8-161PMID 21477382PMCID 3086852
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C and Liver Transplantation

  2012cited by this paper
• The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry

  2008cited by this paper
• Epidemiology of hepatitis C virus infection in Pakistan.

  2008cited by this paper
• Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission

  2008cited by this paper
• Virology Journal

  2008cited by this paper
• Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions

  2007cited by this paper
• Old and emerging therapies in chronic hepatitis C: an update

  2007cited by this paper
• Hepatitis C virus entry into host cells

  2007cited by this paper
• Structure of the catalytic domain of the hepatitis C virus NS2-3 protease

  2006cited by this paper
• Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 Infection

  2006cited by this paper
• [Chronic hepatitis C virus infection].

  2006cited by this paper
• Hepatitis C virus entry: Molecular biology and clinical implications

  2006cited by this paper
• Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway.

  2006cited by this paper
• Hepatitis C Virus Core Protein Blocks Interferon Signaling by Interaction with the STAT1 SH2 Domain

  2006influential reference
• Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

  2006cited by this paper
• Expression of hepatitis C virus nonstructural 4B in transgenic mice

  2006cited by this paper
• Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein.

  2006cited by this paper
• Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci.

  2005cited by this paper
• Challenges and successes in developing new therapies for hepatitis C

  2005cited by this paper
• Evasion of intracellular host defence by hepatitis C virus

  2005cited by this paper
• Intrahepatic CD8+ T‐cell failure during chronic hepatitis C virus infection

  2005cited by this paper
• Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.

  2005cited by this paper
• A Brownian motor mechanism of translocation and strand separation by hepatitis C virus helicase

  2005cited by this paper
• Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins

  2005cited by this paper
• Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.

  2005cited by this paper
• Hepatitis C virus expression suppresses interferon signaling by degrading STAT1.

  2005cited by this paper
• Hepatitis C virus and the immune system: a concise review

  2005cited by this paper
• Mechanism of action of interferon and ribavirin in treatment of hepatitis C

  2005cited by this paper
• Acute viral hepatitis C should be treated.

  2005cited by this paper
• Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy

  2005cited by this paper
• Function follows form: The structure of the N‐terminal domain of HCV NS5A

  2005cited by this paper
• Hepatitis C virus mutation affects proteasomal epitope processing.

  2004cited by this paper
• Host factors and failure of interferon-alpha treatment in hepatitis C virus.

  2004cited by this paper
• Limited T Cell Receptor Diversity of HCV-specific T Cell Responses Is Associated with CTL Escape

  2004cited by this paper
• Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.

  2004cited by this paper
• Structure and Function of the Membrane Anchor Domain of Hepatitis C Virus Nonstructural Protein 5A*

  2004influential reference
• Retrovirus restriction factors.

  2004cited by this paper
• Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.

  2004cited by this paper
• Periodic cycles of RNA unwinding and pausing by hepatitis C virus NS3 helicase

  2004cited by this paper
• Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner.

  2004cited by this paper
• HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing.

  2004cited by this paper
• Host factors and failure of interferon‐α treatment in hepatitis C virus

  2004cited by this paper
• The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity.

  2004cited by this paper
• Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication

  2003cited by this paper
• Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA.

  2003cited by this paper
• Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins

  2003cited by this paper
• Chronic hepatitis C virus infection.

  2003cited by this paper
• Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons

  2003cited by this paper
• L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus

  2003cited by this paper
• The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

  2003cited by this paper
• Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

  2003cited by this paper
• Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

  2003cited by this paper
• In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

  2003cited by this paper
• Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase.

  2003cited by this paper
• The Clearance of Hepatitis C Virus Infection in Chimpanzees May Not Necessarily Correlate with the Appearance of Acquired Immunity

  2003cited by this paper
• IFN‐α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling‐3

  2003cited by this paper
• Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins.

  2002cited by this paper
• Treatment of acute hepatitis C with interferon alfa-2b.

  2002cited by this paper
• The Domains Required to Direct Core Proteins of Hepatitis C Virus and GB Virus-B to Lipid Droplets Share Common Features with Plant Oleosin Proteins*

  2002cited by this paper
• Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon‐α

  2002cited by this paper
• Prevention of spread of hepatitis C

  2002cited by this paper
• The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

  2002cited by this paper
• Expression of Hepatitis C Virus Proteins Induces Distinct Membrane Alterations Including a Candidate Viral Replication Complex

  2002cited by this paper
• Interaction between hepatitis C virus proteins and host cell factors.

  2002cited by this paper
• Epidemiology and clinical presentation of hepatocellular carcinoma.

  2002cited by this paper
• Prevention of spread of hepatitis C

  2002cited by this paper
• Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness.

  2002cited by this paper
• An Amino-terminal Amphipathic α-Helix Mediates Membrane Association of the Hepatitis C Virus Nonstructural Protein 5A*

  2002cited by this paper
• Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

  2002cited by this paper
• Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection1

  2002cited by this paper
• Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions

  2002cited by this paper
• Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

  2002cited by this paper
• Noncytolytic control of viral infections by the innate and adaptive immune response.

  2001cited by this paper
• How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A.

  2001cited by this paper
• Hepatitis C and liver transplantation.

  2001cited by this paper
• Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

  2001cited by this paper
• The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein.

  2001cited by this paper
• Treatment of acute hepatitis C with interferon alfa-2b.

  2001cited by this paper
• Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response

  2001influential reference
• Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection

  2001cited by this paper
• DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection

  2001cited by this paper
• Subcellular Localization, Stability, andtrans-Cleavage Competence of the Hepatitis C Virus NS3-NS4A Complex Expressed in Tetracycline-Regulated Cell Lines

  2000cited by this paper
• Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

  1999cited by this paper
• Diagnostic tests for hepatitis C.

  1999cited by this paper
• Hyperphosphorylation of the Hepatitis C Virus NS5A Protein Requires an Active NS3 Protease, NS4A, NS4B, and NS5A Encoded on the Same Polyprotein

  1999cited by this paper
• Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells.

  1999cited by this paper
• Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

  1999cited by this paper
• Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line

  1999cited by this paper
• Global surveillance and control of hepatitis C

  1999cited by this paper
• Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

  1999cited by this paper
• Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

  1999cited by this paper
• Long-Term Follow-Up of Chimpanzees Inoculated with the First Infectious Clone for Hepatitis C Virus

  1999cited by this paper
• Binding of hepatitis C virus to CD81.

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• RNA-dependent RNA Polymerase Activity of the Soluble Recombinant Hepatitis C Virus NS5B Protein Truncated at the C-terminal Region*

  1998cited by this paper
• Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation

  1998cited by this paper

• Membrane binding promotes oligomerization and functional activation of viral RNA-dependent RNA polymerase

  2025cites this paper
• The HCV-Dependent Inhibition of Nrf1/ARE-Mediated Gene Expression Favours Viral Morphogenesis

  2025cites this paper
• Hepatitis C Virus Resistance-Associated Substitutions in Mexico

  2025cites this paper
• Well-Tempered Metadynamic Simulations Provide Insights and Leads for Designing Effective Allosteric Inhibitors against SARS-CoV-2 RNA-Dependent RNA Polymerase

  2025cites this paper
• The role of pioneering transcription factors, chromatin accessibility and epigenetic reprogramming in oncogenic viruses

  2025cites this paper
• Loop of fate: structural and mechanistic insights into hnRNPA1 binding to the hepatitis C virus RNA

  2025cites this paper
• Advances in Viroporin Function and Structure: A Comparative Analysis of Alphavirus 6K with Well-Characterized Viroporins

  2025cites this paper
• Virtual screening, optimization design, and synthesis analysis of novel benzofuran derivatives as pan-genotypic HCV NS5B polymerase inhibitors using molecular modeling

  2025cites this paper
• Inhibition of hepatitis C virus replication in HepG2 cells via modulation of the Raf-1 and interferon-alpha signaling pathways by thymoquinone

  2025cites this paper
• In silico antiviral properties of Spirulina platensis phycobiliprotein and phycobilin as natural inhibitor for SARS-CoV-2

  2024cites this paper
• Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

  2024cites this paper
• Hepatitis B Virus Infection: A Mini Review

  2024influential citation
• Navigating the Immune Response Landscape of Hepatitis B and Hepatitis C Virus Infections

  2024influential citation
• Exploring the Impact of Different Inflammatory Cytokines on Hepatitis C Virus Infection

  2024cites this paper
• Recent updates on molecular epidemiology of hepatitis C virus in Gujranwala, Pakistan

  2024cites this paper
• Lectibodies as antivirals.

  2024cites this paper
• Investigation into the Neuroprotective and Therapeutic Potential of Plant-Derived Chk2 Inhibitors

  2024cites this paper
• Molecular and Immunological Detection of Hepatitis C Virus in Patients with Chronic Renal Failure

  2024cites this paper
• Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury

  2024cites this paper
• Hepatitis C Virus Prevalence in Hemodialysis Patients in Karbala Province

  2023cites this paper
• Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.

  2023cites this paper
• Pivotal Role of Serum IL-37 In Patients with Chronic HBV and HCV

  2023cites this paper
• NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?

  2023cites this paper
• Exploring boron applications in modern agriculture: anti-fungal activities and mechanisms of phenylboric acid derivatives.

  2023cites this paper
• Oncogenic Viruses and the Epigenome: How Viruses Hijack Epigenetic Mechanisms to Drive Cancer

  2023cites this paper
• Hydrogen Peroxide Inhibits Hepatitis C Virus Replication by Downregulating Hepatitis C Virus Core Levels through E6-Associated Protein-Mediated Proteasomal Degradation

  2023cites this paper
• The Role of Cytosolic Lipid Droplets in Hepatitis C Virus Replication, Assembly, and Release

  2023cites this paper
• Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective

  2022cites this paper
• The roles of epidermal growth factor receptor in viral infections

  2022cites this paper
• Natural flavonoids effectively block the CD81 receptor of hepatocytes and inhibit HCV infection: a computational drug development approach

  2022cites this paper
• Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China

  2022cites this paper
• Comparative genomics and molecular epidemiology on hepatitis virus–induced hepatocellular carcinoma

  2022cites this paper
• Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system

  2022cites this paper
• Socio-economic assessments of Hepatitis C Virus infection: Evidence from Vehari district of Pakistan

  2021cites this paper
• Diagnostic sensitivity of arginase, alpha-1 antitrypsin and alpha-fetoprotein in hepatitis patients

  2021cites this paper
• Liver Organoid and T Cell Coculture Models Cytotoxic T Cell Responses against Hepatitis C Virus

  2021cites this paper
• SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses

  2021cites this paper
• Virion Assembly: From Small Picornaviruses (Picornaviridae) to Large Herpesviruses (Herpesviridae)

  2021cites this paper
• The next generation of HCV vaccines: a focus on novel adjuvant development

  2021cites this paper
• SARS-CoV-2 PANDEMIC: A NARRATIVE REVIEW ON LESSONS AND VIEWPOINTS ARISING FROM BOTH THE HISTORY OF MEDICINE AND FROM THE BIOLOGICAL BEHAVIOUR OF OTHER WELL-KNOWN VIRUSES

  2021cites this paper
• CORRELATION BETWEEN THE ANTIBODY RESPONSE TOWARD SPECIFIC HCV PROTEINS AND HCV VIRAL LOAD

  2021cites this paper
• Review on Hepatitis C

  2021cites this paper
• Pathogens and Carcinogenesis: A Review

  2021cites this paper
• Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.

  2021cites this paper
• HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development

  2021influential citation
• Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis

  2021cites this paper
• Feature-extraction and analysis based on spatial distribution of amino acids for SARS-CoV-2 Protein sequences

  2021cites this paper
• Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome

  2021cites this paper
• Discovery of Novel HCV NS5B polymerase inhibitor, 2‐(3,4‐dimethyl‐5,5‐dioxidobenzo[e]pyrazolo[4,3‐c][1,2]thiazin‐2(4H)‐yl)‐N‐(2‐fluorobenzyl)acetamide via molecular docking and experimental approach

  2021cites this paper
• Detection and Quantification of HCV-RNA by RT-PCR among Anti-HCV Positive Patients

  2020cites this paper
• Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus

  2020cites this paper
• Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs

  2020cites this paper
• MODELLING THE EFFECTS OF HCV PLUS-STRAND RNA INFLUX INTO A CELL DURING HCV REPLICATION

  2020cites this paper
• Spatial Distribution of Amino Acids of the SARS-CoV2 Proteins

  2020cites this paper
• Prospective Study

  2020cites this paper
• Resistance to excision determines efficiency of inhibition of hepatitis C virus RNA-dependent RNA polymerase by nucleotide analogs including sofosbuvir

  2020cites this paper
• Advances in detection of infectious agents by aptamer-based technologies

  2020cites this paper
• Occurrence of aflatoxin in the kernels of Irvingia gabonensis (Aubry Lecomte ex O Rorke) Baill sold in parts of Nigeria

  2020cites this paper
• Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature

  2020cites this paper
• SYNTHESIS CHARACTERIZATION AND DOCKING STUDY OF HCV NS3/4A PROTEASE INHIBITOR MOLECULES

  2020cites this paper
• Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination

  2020cites this paper
• The remarkable history of the hepatitis C virus

  2019cites this paper
• Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens

  2019cites this paper
• The phylogenetic approach for viral infectious disease evolution and epidemiology: An updating review

  2019cites this paper
• IN-SILICO T-CELL EPITOPE PREDICTION TOOL OF HEPATITIS C VIRUS (HCV)

  2019cites this paper
• Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria

  2019cites this paper
• Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients.

  2019cites this paper
• Novel Quinazoline derivatives inhibited HCV Serine protease and viral replication in Huh-7 cells

  2019cites this paper
• In silico investigation of hepatitis c virus: a novel perspective into targeted viral inhibition of NS3 helicase, NS 3/4a protease and NS5b RNA dependent RNA polymerase.

  2019cites this paper
• DNA sequences homologous to hepatitis C virus (HCV) in the extrachromosomal circular DNA in peripheral blood mononuclear cells of HCV-negative subjects

  2019cites this paper
• Laboratory and Molecular Diagnosis of Hepatitis C and Resistance Testing

  2019cites this paper
• Genetically encoded FRET sensor to detect double- stranded RNA during viral infection

  2019cites this paper
• Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review

  2019cites this paper
• Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A.

  2018cites this paper
• The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma

  2018cites this paper
• Event-related evoked potential versus clinical tests in assessment of subclinical cognitive impairment in chronic hepatitis C virus

  2018cites this paper
• ASSESSMENT OF KNOWLEDGE OF STUDENTS AT PUNJAB UNIVERSITY CAMPUS GUJRANWALA REGARDING FACTORS CONTRIBUTING FOR HEPATITIS C

  2018cites this paper
• Rheumatology to hepatology cross talk: An evidence based update on the treat to target strategy in hepatitis-C related extrahepatic autoimmune syndromes

  2018cites this paper
• Development and validation of a TaqMan RT-qPCR for the detection of convert mortality nodavirus (CMNV).

  2018cites this paper
• New phenylaniline derivatives as modulators of amyloid protein precursor metabolism.

  2018cites this paper
• Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges

  2018cites this paper
• Genetic Diversity of Hepatitis C Virus Among Blood Donors and Patients with Clinical Hepatitis in Ibadan, Nigeria.

  2018cites this paper
• Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.

  2018cites this paper
• EFFECTS OF SHORT RNA SEQUENCES ANALOGS AGAINST HCV GENOTYPE 4(A) IN REPLICON CELLS BY

  2018cites this paper
• Iraqi Journal of Medical Sciences Aims and Scope

  2018influential citation
• Structural Flexibility in HCV NS5B Polymerase and Molecular Modelling of Anti-HCV Drugs

  2018cites this paper
• FREQUENCY OF HEPATITIS C VIRUS GENOTYPES /SUBTYPES ASSOCIATION WITH RESPONSE TO THERAPY IN A SAMPLE OF HCV INFECTED IRAQI PATIENTS

  2018cites this paper
• The evaluation of point of care testing and dried blood spots to assess diagnostic accuracy of HCV infection as part of Sero-Molecular surveillance in people most-at-risk for hepatitis C virus

  2018cites this paper
• Hepatitis C Virus Core Protein Increases Expression of DR 4 and DR 5 in Peripheral Blood Mononuclear Cells

  2018cites this paper
• Recent trends in molecular epidemiology of Hepatitis C virus in Mardan, KPK Pakistan.

  2018cites this paper
• Hepatitis C virus: Morphogenesis, infection and therapy

  2018cites this paper
• An Overview of Risk Factors of Vertical Transmission of Hepatitis C Virus and Treatment Options for Chronic HCV

  2018cites this paper
• Hepatitis C virus infection and chronic renal disease: A review

  2018cites this paper
• Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis

  2017cites this paper
• Epidemiology of Hepatitis C Infection in Pakistan: Current Estimate and Major Risk Factors.

  2017cites this paper
• From in-silico immunogenicity verification to in vitro expression of recombinant Core-NS3 fusion protein of HCV.

  2017cites this paper
• Enhanced molecular assays using strand-displacing polymerases and loop-mediated amplification (LAMP) with Bioluminescent Assay in Real Time (BART)

  2017cites this paper
• Designing and molecular docking of cyclic peptides against HCV NS3 protease.

  2017cites this paper
• Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.

  2017cites this paper
• Improving ascertainment and treatment rates of chronic viral hepatitis

  2017cites this paper